Table 1 (abstract P305). See text for description

Patients (n)

4

11

Female n(%)

3 (25)

10 (9)

Age (mean (SD))

13.80 (1.91)

13.45 (2.72)

Disease duration (mean (SD))

6.47 (4.22)

6.17 (2.71)

 Acute cutaneous, n (%)

4 (100.0)

6 (54.5)

 Chronic cutaneous, n (%)

0 (0.0)

0 (0.0)

 Alopecia, n (%)

0 (0.0)

1 (9.1)

 Oral or nasal ulcers, n (%)

2 (50.0)

7 (63.6)

 Arthritis, n (%)

3 (75.0)

4 (36.4)

 Serositis, n (%)

0 (0.0)

2 (18.2)

 Renal, n (%)

1 (25.0)

2 (18.2)

 Neurological, n (%)

0 (0.0)

0 (0.0)

 Hemolytic anemia, n (%)

1 (25.0)

4 (36.4)

 Leukopenia, n (%)

4 (100.0)

9 (81.8)

 Thrombocytopenia, n (%)

3 (75.0)

5 (45.5)

 ANA+, n (%)

4 (100.0)

11 (100.0)

 Anti-dsDNA+, n (%)

4 (100.0)

11 (100.0)

 Anti-Sm+, n (%)

1 (25.0)

2 (18.2)

 LAC, n (%)

0 (0.0)

1 (9.1)

 anti-cardiolipin, n (%)

2 (50.0)

2 (18.2)

 anti-beta2GPI+, n (%)

2 (50.0)

2 (18.2)

 Low complement, n (%)

4 (100.0)

11 (100.0)

 C3, mean (SD) mg/dL

40.25 (5.51)

52.73 (20.81)

 C4, mean (SD) mg/dL

3.67 (2.89)

4.60 (2.72)

 SLEDAI at diagnosis, mean (SD)

12.75 (4.50)

12.18 (7.14)

SLEDAI at last follow-up, mean (SD)

0.00 (0.00)

1.36 (1.43)

 PDN, n (%)

3 (75.0)

11 (100.0)

 HCQ, n (%)

4 (100.0)

11 (100.0)

 MMF, n (%)

4 (100.0)

11 (100.0)

 RTX, n (%)

0 (0.0)

2 (18.2)